A Phase III clinical study switching paroxysmal nocturnal hemoglobinuria (PNH) patients from eculizumab treatment to Coversin
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2018
Price : $35 *
At a glance
- Drugs Nomacopan (Primary) ; Eculizumab
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Acronyms ASSET
- 30 Sep 2018 Status changed from planning to recruiting, according to an Akari Therapeutics media release.
- 06 Feb 2018 According to an Akari media release, company plans to initiate this trial in the end of first quarter of 2018.
- 08 Dec 2017 According to an Akari media release, company plans to initiate this trial in the second half of 2018 and will include Soliris switch patients.